Analyst Josh Jennings of TD Cowen maintained a Buy rating on Humacyte (HUMA – Research Report), reducing the price target to $7.50.
Josh Jennings has given his Buy rating due to a combination of factors surrounding Humacyte’s recent developments. The company has successfully launched SYMVESS, their acellular tissue-engineered vessel, for vascular trauma, marking it as their first FDA-approved commercial indication. This launch is a significant achievement, as it provides a ready-to-use solution for complex arterial injuries, which is expected to drive strong market adoption.
Furthermore, Humacyte’s strategic approach to market analysis and commercial execution, coupled with their focus on securing positive VAC approval and adoption by vascular trauma centers, positions them well for future growth. The positive early trends in the U.S. vascular trauma launch and favorable feedback from vascular surgeons further reinforce the potential for SYMVESS to gain traction in the market, supporting Jennings’s optimistic outlook and Buy rating.
In another report released on March 7, Benchmark Co. also maintained a Buy rating on the stock with a $17.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com